“It is great news to have a success with a second anti-amyloid Alzheimer’s drug,” said Professor Sir John Hardy (UCL Queen Square Institute of Neurology) who added, “This should dispel any lingering doubts about this approach.”
Read: Times (£), More: Independent, i News, Herald